4303-41-7Relevant academic research and scientific papers
REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS
-
Paragraph 001143; 001146-001147, (2022/01/05)
The present disclosure provides compounds of Formula IA and Formula IB and their pharmaceutical compositions as selective agonists of REV-ERB-α: where R1, R2, R3, R4, R5, RX1, RX2, nA, nB, X, Y, and Z are described herein. The compounds are useful in various methods and uses, such as in the treatment of diseases including hyperglycemia, dyslipidemia, atherosclerosis, and autoimmune and inflammatory disorders or diseases, and as cancer therapeutics, such as for the treatment of glioblastoma, hepatocellular carcinoma, and colorectal cancer, and for immune-oncology purposes.
Process for the preparation of thiophosphoric acid esters
-
, (2008/06/13)
A process for the preparation of a compound of the formula STR1 in which R is alkyl, X is oxygen or sulphur and R' is hydrogen or alkyl, comprising reacting a thiophosphate of the formula STR2 in which M is a cation other than NH4≈, with an ethylmercapto compound of the formula STR3 in which Y is a fugitive group, in a polar reaction medium at a temperature between about 30° and 80° C. and at a pH between about 2 and 9. Advantageously X is oxygen and the thiophosphate is produced by reaction of a dialkyl phosphite of the formula STR4 with sulphur in the presence of an organic base in an organic solvent and subsequent extraction with aqueous MOH solution. Also Y is advantageously chlorine and the ethylmercapto compound is prepared by heating the corresponding alcohol to about 40°-100° C. and passing hydrogen chloride gas into the pre-warmed alcohol, the reaction solution being used directly without working up.
